Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 57.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (33.1%)
  • Dividend yield for the last twelve months 0.8%
  • Free cash flow yield -1.6% (LTM)
  • Share price is 151.7% higher than minimum and 22.3% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (37.0x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $222.4 mln (-0.031% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+1.2%)746.37
year average price 805.56  


year start price 912.75 2024-09-05

max close price 935.02 2024-09-12

min close price 625.65 2025-08-08

current price 737.83 2025-09-04
Common stocks: 900 605 000

Dividend Yield:  0.8%
FCF Yield LTM: -1.6%
EV / LTM EBITDA: 37.0x
EV / EBITDA annualized: 23.9x
Last revenue growth (y/y):  +37.6%
Last growth of EBITDA (y/y):  +77.9%
Historical revenue growth:  +23.8%
Historical growth of EBITDA:  +42.3%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 672 185
Net Debt ($m): 36 434
EV (Enterprise Value): 708 619
EBITDA LTM ($m): 19 131
EV / LTM EBITDA: 37.0x
Price to Book: 46.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-04prnewswire.com

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers

2025-09-04fool.com

Where Will Eli Lilly Be in 3 Years?

2025-09-04seekingalpha.com

Eli Lilly's Stock Fall Is An Opportunity

2025-09-02zacks.com

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

2025-09-02zacks.com

Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales

2025-09-01barrons.com

Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.

2025-08-31reuters.com

Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study

2025-08-29invezz.com

Eli Lilly joins forces with China tech giant to expand obesity drug market

2025-08-28proactiveinvestors.co.uk

Eli Lilly halts UK shipments of Mounjaro diabetes and weight-loss drug

2025-08-27reuters.com

Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data